Treats major depressive disorder (MDD). ANDA 78421, held by Dr. Reddy's Laboratories. Venlafaxine Hydrochloride.
As of Nov 21, 2026, ANDA 78421 (Venlafaxine Hydrochloride), held by Dr. Reddy's Laboratories, was first approved by FDA on May 6, 2011, with 1 approved supplement and 0 published complete response letters.
Venlafaxine hydrochloride extended-release capsules are serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of:
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 6, 2011 | Original application | Approved | None posted |
| Venlafaxine HydrochlorideEQ 37.5MG BASE · capsule, extended release;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 75MG BASE · capsule, extended release;oral | Venlafaxine Hydrochloride | Rx |
| Venlafaxine HydrochlorideEQ 150MG BASE · capsule, extended release;oral | Venlafaxine Hydrochloride | Rx |
| Sep 19, 2012 | Supplement 3Labeling · Standard review | Approved | None posted |
| May 6, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters